Report cover image

Global Self-replicating mRNA Vaccines Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 195 Pages
SKU # APRC20279155

Description

Summary

According to APO Research, the global Self-replicating mRNA Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Self-replicating mRNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Self-replicating mRNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Self-replicating mRNA Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Self-replicating mRNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Self-replicating mRNA Vaccines market include Aldevron, Arcturus Therapeutics, BioNTech, Chimeron Bio, CSL, Elixirgen Therapeutics, Gritstone Bio, Precision Nanosystems and Replicate Bioscience, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Self-replicating mRNA Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Self-replicating mRNA Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Self-replicating mRNA Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Self-replicating mRNA Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Self-replicating mRNA Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Self-replicating mRNA Vaccines sales, projected growth trends, production technology, application and end-user industry.


Self-replicating mRNA Vaccines Segment by Company


Aldevron

Arcturus Therapeutics

BioNTech

Chimeron Bio

CSL

Elixirgen Therapeutics

Gritstone Bio

Precision Nanosystems

Replicate Bioscience

VaxEquity

Ziphius Vaccines

GSK

Immorna

Self-replicating mRNA Vaccines Segment by Type


Preventive Medicine

Medicine

Self-replicating mRNA Vaccines Segment by Application


Infectious Disease

Cancer

Others

Self-replicating mRNA Vaccines Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Self-replicating mRNA Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Self-replicating mRNA Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Self-replicating mRNA Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Self-replicating mRNA Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Self-replicating mRNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Self-replicating mRNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Self-replicating mRNA Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Self-replicating mRNA Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Self-replicating mRNA Vaccines industry.
Chapter 3: Detailed analysis of Self-replicating mRNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Self-replicating mRNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Self-replicating mRNA Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Self-replicating mRNA Vaccines Sales Value (2020-2031)
1.2.2 Global Self-replicating mRNA Vaccines Sales Volume (2020-2031)
1.2.3 Global Self-replicating mRNA Vaccines Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Self-replicating mRNA Vaccines Market Dynamics
2.1 Self-replicating mRNA Vaccines Industry Trends
2.2 Self-replicating mRNA Vaccines Industry Drivers
2.3 Self-replicating mRNA Vaccines Industry Opportunities and Challenges
2.4 Self-replicating mRNA Vaccines Industry Restraints
3 Self-replicating mRNA Vaccines Market by Company
3.1 Global Self-replicating mRNA Vaccines Company Revenue Ranking in 2024
3.2 Global Self-replicating mRNA Vaccines Revenue by Company (2020-2025)
3.3 Global Self-replicating mRNA Vaccines Sales Volume by Company (2020-2025)
3.4 Global Self-replicating mRNA Vaccines Average Price by Company (2020-2025)
3.5 Global Self-replicating mRNA Vaccines Company Ranking (2023-2025)
3.6 Global Self-replicating mRNA Vaccines Company Manufacturing Base and Headquarters
3.7 Global Self-replicating mRNA Vaccines Company Product Type and Application
3.8 Global Self-replicating mRNA Vaccines Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Self-replicating mRNA Vaccines Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Self-replicating mRNA Vaccines Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Self-replicating mRNA Vaccines Market by Type
4.1 Self-replicating mRNA Vaccines Type Introduction
4.1.1 Preventive Medicine
4.1.2 Medicine
4.2 Global Self-replicating mRNA Vaccines Sales Volume by Type
4.2.1 Global Self-replicating mRNA Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Self-replicating mRNA Vaccines Sales Volume by Type (2020-2031)
4.2.3 Global Self-replicating mRNA Vaccines Sales Volume Share by Type (2020-2031)
4.3 Global Self-replicating mRNA Vaccines Sales Value by Type
4.3.1 Global Self-replicating mRNA Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Self-replicating mRNA Vaccines Sales Value by Type (2020-2031)
4.3.3 Global Self-replicating mRNA Vaccines Sales Value Share by Type (2020-2031)
5 Self-replicating mRNA Vaccines Market by Application
5.1 Self-replicating mRNA Vaccines Application Introduction
5.1.1 Infectious Disease
5.1.2 Cancer
5.1.3 Others
5.2 Global Self-replicating mRNA Vaccines Sales Volume by Application
5.2.1 Global Self-replicating mRNA Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Self-replicating mRNA Vaccines Sales Volume by Application (2020-2031)
5.2.3 Global Self-replicating mRNA Vaccines Sales Volume Share by Application (2020-2031)
5.3 Global Self-replicating mRNA Vaccines Sales Value by Application
5.3.1 Global Self-replicating mRNA Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Self-replicating mRNA Vaccines Sales Value by Application (2020-2031)
5.3.3 Global Self-replicating mRNA Vaccines Sales Value Share by Application (2020-2031)
6 Self-replicating mRNA Vaccines Regional Sales and Value Analysis
6.1 Global Self-replicating mRNA Vaccines Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Self-replicating mRNA Vaccines Sales by Region (2020-2031)
6.2.1 Global Self-replicating mRNA Vaccines Sales by Region: 2020-2025
6.2.2 Global Self-replicating mRNA Vaccines Sales by Region (2026-2031)
6.3 Global Self-replicating mRNA Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Self-replicating mRNA Vaccines Sales Value by Region (2020-2031)
6.4.1 Global Self-replicating mRNA Vaccines Sales Value by Region: 2020-2025
6.4.2 Global Self-replicating mRNA Vaccines Sales Value by Region (2026-2031)
6.5 Global Self-replicating mRNA Vaccines Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Self-replicating mRNA Vaccines Sales Value (2020-2031)
6.6.2 North America Self-replicating mRNA Vaccines Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Self-replicating mRNA Vaccines Sales Value (2020-2031)
6.7.2 Europe Self-replicating mRNA Vaccines Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Self-replicating mRNA Vaccines Sales Value (2020-2031)
6.8.2 Asia-Pacific Self-replicating mRNA Vaccines Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Self-replicating mRNA Vaccines Sales Value (2020-2031)
6.9.2 South America Self-replicating mRNA Vaccines Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Self-replicating mRNA Vaccines Sales Value (2020-2031)
6.10.2 Middle East & Africa Self-replicating mRNA Vaccines Sales Value Share by Country, 2024 VS 2031
7 Self-replicating mRNA Vaccines Country-level Sales and Value Analysis
7.1 Global Self-replicating mRNA Vaccines Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Self-replicating mRNA Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Self-replicating mRNA Vaccines Sales by Country (2020-2031)
7.3.1 Global Self-replicating mRNA Vaccines Sales by Country (2020-2025)
7.3.2 Global Self-replicating mRNA Vaccines Sales by Country (2026-2031)
7.4 Global Self-replicating mRNA Vaccines Sales Value by Country (2020-2031)
7.4.1 Global Self-replicating mRNA Vaccines Sales Value by Country (2020-2025)
7.4.2 Global Self-replicating mRNA Vaccines Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.5.2 USA Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Canada Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.8.2 Germany Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.9.2 France Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.9.3 France Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.11.2 Italy Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.12.2 Spain Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.13.2 Russia Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.16.2 China Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.16.3 China Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.17.2 Japan Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.19.2 India Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.19.3 India Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.20.2 Australia Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.24.2 Chile Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.26.2 Peru Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.28.2 Israel Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.29.2 UAE Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.31.2 Iran Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Self-replicating mRNA Vaccines Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Self-replicating mRNA Vaccines Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Self-replicating mRNA Vaccines Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Aldevron
8.1.1 Aldevron Comapny Information
8.1.2 Aldevron Business Overview
8.1.3 Aldevron Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.1.4 Aldevron Self-replicating mRNA Vaccines Product Portfolio
8.1.5 Aldevron Recent Developments
8.2 Arcturus Therapeutics
8.2.1 Arcturus Therapeutics Comapny Information
8.2.2 Arcturus Therapeutics Business Overview
8.2.3 Arcturus Therapeutics Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.2.4 Arcturus Therapeutics Self-replicating mRNA Vaccines Product Portfolio
8.2.5 Arcturus Therapeutics Recent Developments
8.3 BioNTech
8.3.1 BioNTech Comapny Information
8.3.2 BioNTech Business Overview
8.3.3 BioNTech Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.3.4 BioNTech Self-replicating mRNA Vaccines Product Portfolio
8.3.5 BioNTech Recent Developments
8.4 Chimeron Bio
8.4.1 Chimeron Bio Comapny Information
8.4.2 Chimeron Bio Business Overview
8.4.3 Chimeron Bio Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.4.4 Chimeron Bio Self-replicating mRNA Vaccines Product Portfolio
8.4.5 Chimeron Bio Recent Developments
8.5 CSL
8.5.1 CSL Comapny Information
8.5.2 CSL Business Overview
8.5.3 CSL Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.5.4 CSL Self-replicating mRNA Vaccines Product Portfolio
8.5.5 CSL Recent Developments
8.6 Elixirgen Therapeutics
8.6.1 Elixirgen Therapeutics Comapny Information
8.6.2 Elixirgen Therapeutics Business Overview
8.6.3 Elixirgen Therapeutics Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.6.4 Elixirgen Therapeutics Self-replicating mRNA Vaccines Product Portfolio
8.6.5 Elixirgen Therapeutics Recent Developments
8.7 Gritstone Bio
8.7.1 Gritstone Bio Comapny Information
8.7.2 Gritstone Bio Business Overview
8.7.3 Gritstone Bio Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.7.4 Gritstone Bio Self-replicating mRNA Vaccines Product Portfolio
8.7.5 Gritstone Bio Recent Developments
8.8 Precision Nanosystems
8.8.1 Precision Nanosystems Comapny Information
8.8.2 Precision Nanosystems Business Overview
8.8.3 Precision Nanosystems Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.8.4 Precision Nanosystems Self-replicating mRNA Vaccines Product Portfolio
8.8.5 Precision Nanosystems Recent Developments
8.9 Replicate Bioscience
8.9.1 Replicate Bioscience Comapny Information
8.9.2 Replicate Bioscience Business Overview
8.9.3 Replicate Bioscience Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.9.4 Replicate Bioscience Self-replicating mRNA Vaccines Product Portfolio
8.9.5 Replicate Bioscience Recent Developments
8.10 VaxEquity
8.10.1 VaxEquity Comapny Information
8.10.2 VaxEquity Business Overview
8.10.3 VaxEquity Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.10.4 VaxEquity Self-replicating mRNA Vaccines Product Portfolio
8.10.5 VaxEquity Recent Developments
8.11 Ziphius Vaccines
8.11.1 Ziphius Vaccines Comapny Information
8.11.2 Ziphius Vaccines Business Overview
8.11.3 Ziphius Vaccines Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.11.4 Ziphius Vaccines Self-replicating mRNA Vaccines Product Portfolio
8.11.5 Ziphius Vaccines Recent Developments
8.12 GSK
8.12.1 GSK Comapny Information
8.12.2 GSK Business Overview
8.12.3 GSK Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.12.4 GSK Self-replicating mRNA Vaccines Product Portfolio
8.12.5 GSK Recent Developments
8.13 Immorna
8.13.1 Immorna Comapny Information
8.13.2 Immorna Business Overview
8.13.3 Immorna Self-replicating mRNA Vaccines Sales, Value and Gross Margin (2020-2025)
8.13.4 Immorna Self-replicating mRNA Vaccines Product Portfolio
8.13.5 Immorna Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Self-replicating mRNA Vaccines Value Chain Analysis
9.1.1 Self-replicating mRNA Vaccines Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Self-replicating mRNA Vaccines Sales Mode & Process
9.2 Self-replicating mRNA Vaccines Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Self-replicating mRNA Vaccines Distributors
9.2.3 Self-replicating mRNA Vaccines Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.